Having A Known Elemental Analysis (e.g., Antibiotic, Etc.) Patents (Class 424/116)
  • Patent number: 10046088
    Abstract: Nano scale collagen particles can be obtained from an embrittling and attrition process that reduces the size of collagen particles to the nano scale. These nano scale collagen particles have many favorable properties such as providing beneficial and enhanced properties for cell seeding and wound healing. The nano scale collagen particles can be included in biocompatible (e.g., biostable or biodegradable) compositions and are useful for wound treatment and management, as well as in cell cultures and tissue engineering implants.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: August 14, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Hengky Chang, Henry Leung
  • Patent number: 9861619
    Abstract: Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 9, 2018
    Assignee: The University of Chicago
    Inventors: Robert S. Daum, Susan Boyle-Vavra
  • Patent number: 9492496
    Abstract: The present application describes organic compounds of Formula (I) and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: November 15, 2016
    Assignee: Novartis AG
    Inventors: Simon Bushell, Matthew J. Lamarche, Jennifer Leeds, Lewis Whitehead
  • Patent number: 9072776
    Abstract: In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: July 7, 2015
    Assignee: Glycanova AS
    Inventor: Bjørn Kristiansen
  • Patent number: 8562952
    Abstract: Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 22, 2013
    Assignee: Cedars-Sinai Medical Center
    Inventor: Henry C. Lin
  • Patent number: 8524253
    Abstract: This invention is directed to a bone regeneration device including fascia and demineralized bone matrix mixed at a temperature not exceeding about 40° C. and lyophilized into the bone regeneration device, methods of preparing such a bone regeneration device and methods of treating bone defects using such a bone regeneration device.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: September 3, 2013
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Keith Matthew Kinnane, Susan J. Drapeau
  • Patent number: 8388935
    Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 8197805
    Abstract: Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: June 12, 2012
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 8168199
    Abstract: A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: May 1, 2012
    Inventors: Hans-Ulrich Demuth, Ants Kask, Huu Phuc Nguyen, Stephan von Hoersten, Susanne Kruber, Matthias Hoffmann
  • Patent number: 8110177
    Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 7, 2012
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 7964203
    Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: June 21, 2011
    Inventor: Thomas T. Yamashita
  • Patent number: 7939060
    Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: May 10, 2011
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shigeto Uchiyama, Tomomi Ueno, Megumi Kumemura, Kiyoko Imaizumi, Kyosuke Masaki, Seiichi Shimizu
  • Patent number: 7862818
    Abstract: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: January 4, 2011
    Assignee: Human Genome Sciences, Inc.
    Inventors: Viktor Roschke, Craig A. Rosen, Steven M. Ruben
  • Patent number: 7851439
    Abstract: Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: December 14, 2010
    Assignee: Novartis AG
    Inventors: Simon Bushell, Matthew LaMarche, Michael J. Patane, Lewis Whitehead
  • Patent number: 7736622
    Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: June 15, 2010
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 7615207
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: November 10, 2009
    Assignee: Cedars-Sinai Medical Center
    Inventor: Henry C. Lin
  • Patent number: 7608245
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: October 27, 2009
    Assignee: Cedars-Sinai Medical Center
    Inventor: Henry C. Lin
  • Publication number: 20090196867
    Abstract: The invention provides a method for treating fatigue and/or mood disorders and/or improving satiety and/or vitality in a subject in need thereof, comprising the step of administrating an effective amount of a soy kefir powder to said subject.
    Type: Application
    Filed: November 26, 2008
    Publication date: August 6, 2009
    Applicant: KCLM RESEARCH IN NUTRITION INC.
    Inventor: Stan Kubow
  • Patent number: 7435420
    Abstract: The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV—like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36).
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: October 14, 2008
    Assignee: Probiodrug AG
    Inventors: Stephan von Hoersten, Ants Kask, Hans-Ulrich Demuth, Huu Phuc Nguyen, Susanne Kruber, Matthias Hoffmann
  • Patent number: 7345089
    Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: March 18, 2008
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shigeto Uchiyama, Tomomi Ueno, Megumi Kumemura, Kiyoko Imaizumi, Kyosuke Masaki, Seiichi Shimizu
  • Patent number: 7261902
    Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: August 28, 2007
    Inventor: Thomas T. Yamashita
  • Patent number: 7256024
    Abstract: A novel tyrosyl diester antibiotic is obtained from fermentation of a recombinant strain of Streptomyces lividans designated Stretomyces lividans WD 15684 (ATCC-202143). The new antibiotic, designated tyrissamycin, exhibits antibacterial activity, particularly against gram-positive bacteria.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 14, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingfang Q. Cutrone, Lyndon M. Foster, Kimberly D. Krampitz, Stephen W. Mamber, Grace A. McClure, Todd C. Peterson, Lisa C. Rupar, Katie A. Thompson
  • Patent number: 7244412
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: July 17, 2007
    Assignee: Cedars-Sinai Medical Center
    Inventor: Henry C. Lin
  • Patent number: 7132104
    Abstract: The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36).
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: November 7, 2006
    Assignee: Probiodrug AG
    Inventors: Stephan von Horsten, Ants Kask, Hans-Ulrich Demuth, Huu Phuc Nguyen, Susanne Kruber, Matthias Hoffmann
  • Patent number: 7090856
    Abstract: An anti-fouling agent derived by culturing Vibrio alginolyticus in a suitable aqueous solution as well as a newly isolated strain of V. alginolyticus (DSM 15590) for producing the anti-fouting agent. The anti-fouling agent can be used as a component to produce other anti-fouling compositions, Depending on the use, the anti-fouling agent derived from V. alginolyricus may be use directly, or subject to further purification.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: August 15, 2006
    Assignee: Hong Kong University of Science and Technology
    Inventors: Pei-Yuan Qian, Serguei Dobretsov, Tilmann Harder, Chun Kwan Stanley Lau
  • Patent number: 7081239
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: July 25, 2006
    Assignee: Cedars-Sinai Medical Center Burns and Allen Research Center
    Inventor: Henry C. Lin
  • Patent number: 7048906
    Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: May 23, 2006
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 6953585
    Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: October 11, 2005
    Inventor: Thomas T. Yamashita
  • Patent number: 6861053
    Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: March 1, 2005
    Assignee: Cedars-Sinai Medical Center
    Inventors: Henry C. Lin, Mark Pimentel
  • Patent number: 6855524
    Abstract: The invention concerns a method for producing exopolysaccharides by fermenting micro-organisms characterised in that it consists in carrying out the fermentation in a nutrient medium comprising at least a source of carbon available to the micro-organisms and at least a source of nitrogen, said source being derived from a fraction of carob seed.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: February 15, 2005
    Assignee: Danisco USA Inc.
    Inventors: Olivier Nore, Jean-Luc Simon
  • Patent number: 6844182
    Abstract: This invention is directed to Bacillus mutants which produce a factor which potentiates the pesticidal activity of a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 18, 2005
    Assignee: Valent BioSciences Corporation
    Inventors: Helle Outtrup, William D. Lidster, Susan C. MacIntosh, Robert L. Starnes, Denise Carol Manker
  • Patent number: 6773717
    Abstract: The present invention provides improved chlortetracycline-containing animal feed compositions and processes and apparatuses for their preparation. In certain embodiments, raw fermentation broth comprising chlortetracycline is divided into two portions. The first portion is mixed with a compound that complexes chlortetracycline. The second portion is acidified and the solids are removed. The acidified liquid is treated with a complexing agent to produced a chlortetracycline complex. The first and second portions thus treated are then mixed and the mixture is passed on to a filter press or other means for separation of the solids to produce a wet cake comprising complexed chlortetracycline. In alternative embodiments, the second portion may be acidified and filtered and admixed with the first portion prior to the complexing step. The resulting mixture is passed on to a filter press or other means for separation of the solids.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: August 10, 2004
    Assignee: Pennfield Oil Company
    Inventor: Willis L. Winstrom
  • Publication number: 20040010314
    Abstract: A bone replacement material for use in a treatment for repairing a vertebral body compression fracture is formed into a pellet having a roughly polyhedral shape. Each pellet having the roughly polyhedral shape has a pair of opposite surfaces, in which one of the opposite surfaces is inclined with respect to the other surface for a predetermined angle. The angle is preferably in the range of 10 to 60°. Further, the volume of each pellet of the bone replacement material 1 is in the range of 13 to 239 mm3. Furthermore, the bone replacement material is formed of calcium phosphate based compound having the Ca/P ratio of 1.0 to 2.0. By using such a bone replacement material, it is possible to carry out packing operation of the bone replacement material into a collapsed vertebral body smoothly, reliably and safely.
    Type: Application
    Filed: June 10, 2003
    Publication date: January 15, 2004
    Applicants: PENTAX Corporation, Hiromi MATSUZAKI
    Inventors: Hiromi Matsuzaki, Yoshie Tominaga
  • Patent number: 6524600
    Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc. Further, an aqueous composition containing 10 to 50% w/w of a molasses and lignosulfonate, as well as 0.001 to 10% w/w of gallic acid and a yeast extract is also disclosed. In addition, the composition does not include nitrogen, phosphorous, zinc, iron or manganese.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: February 25, 2003
    Inventor: Thomas T. Yamashita
  • Patent number: 6472377
    Abstract: Disclosed is a gene, termed “S-yneS,” found in Streptococcus pneumoniae, which is essential for survival for a wide range of bacteria. This gene and the S-yneS polypeptide that it encodes, as well as homologs and orthologs thereof (collectively referred to as “yneS” genes and polypeptides) can be used to identify antibacterial agents for treating a broad spectrum of bacterial infections.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 29, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christian Fritz, Philip Youngman, Luz-Maria Guzman
  • Patent number: 6406691
    Abstract: The present invention relates to a factor that potentiates the pesticidal activity of a Bacillus related pesticide as well as methods for isolating and identifying said factor. The invention further relates to pesticidal compositions comprising the factor as well as methods of using the pesticidal compositions to control a pest and decrease the resistance of a pest to a pesticide and potentiate a Bacillus related pesticide.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: June 18, 2002
    Assignee: Valent Biosciences Corp.
    Inventors: Denise C. Manker, William D. Lidster, Susan C. MacIntosh, Robert L. Starnes
  • Patent number: 6380245
    Abstract: The present invention relates to novel antibiotics TKR1912-I having the following formula I and TKR1912-II having the following formula II or pharmacologically acceptable salts thereof, which are useful as a remedy for fungal infections, as well as a process for producing them and a microorganism capable of producing them.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: April 30, 2002
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Takesako Kazutoh, Yoshie Yoshikawa, Eiko Koyama, Tomoko Masuda, Ikunoshin Kato
  • Patent number: 6365207
    Abstract: A food or pharmaceutical composition including a liquid composition comprising the liquid fermentation broth product of a biologically active substance, in a carbohydrate medium other than dairy whey wherein said liquid fermentation broth product has not been subject to any concentrating or drying steps prior to introduction of the broth product into said food or pharmaceutical composition is provided.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: April 2, 2002
    Assignee: Rhodia Inc.
    Inventors: Craig Alan Hoppe, Jeanette Lawrence, Amr Shaheed
  • Patent number: 6328961
    Abstract: A novel tyrosyl diester antibiotic is obtained from fermentation of a recombinant strain of Streptomyces lividans designated Streptomyces lividans WD 15684 (ATCC-202143). The new antibiotic, designated tyrissamycin, exhibits antibacterial activity, particularly against gram-positive bacteria.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: December 11, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingfang Cutrone, Lyndon M. Foster, Kimberly Krampitz, Stephen W. Mamber, Grace McClure, Todd C. Peterson, Lisa C. Rupar, Katie A. Thompson
  • Patent number: 6239115
    Abstract: Disclosed are dry flowables containing polyoxin compound, surfactant and water-soluble inorganic material. The dry flowables of the present invention have good friability, dispersibility and suspensibilitv when mixed with water, and have an excellent characteristic that they can efficiently bring out the activity of polyoxin compounds as agricultural chemicals.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: May 29, 2001
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Jun Tokumura, Shinichiro Kochi, Tomoki Yoshimura
  • Patent number: 6214875
    Abstract: A group of specific branched-chain fatty acids, with significant anticancer effects on human and animals; methods of making using either chemical synthesis or biosynthesis methods; and methods of treating cancer.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: April 10, 2001
    Inventor: Zhenhua Yang
  • Patent number: 6214789
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: April 10, 2001
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Patent number: 6187326
    Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc. Further, an aqueous composition containing 10 to 50% w/w of a molasses and lignosulfonate, as well as 0.001 to 10% w/w of gallic acid and a yeast extract is also disclosed. In addition, the composition does not include nitrogen, phosphorous, zinc, iron or manganese.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: February 13, 2001
    Inventor: Thomas T. Yamashita
  • Patent number: 6187800
    Abstract: A method for treating or preventing mastitis in mammals is disclosed. The method contemplates the intramammary injection or dipping the teat with micrococcin antibiotics, preferably micrococcin P1 or P2, which do not interfere with the production of cheese and yoghurt using milk from treated animals. Hydrophobic antibiotics such as micrococcin P1 or P2 can be administered prior to infection to effectively suppress the rate, severity, and duration of subsequent bacterial infection, or can be administered subsequent to infection to effectively treat mastitis.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 13, 2001
    Assignee: Novartis Animal Health U.S., Inc.
    Inventors: Bruno Suri, Catherine Georges, John Edmondson Peel
  • Patent number: 6068839
    Abstract: Novel antibiotics useful as a remedy for fungal infections and a process for producing antibiotic TKR1912-I or pharmacologically acceptable salts thereof, which substances have such plysicochemical properties that (1) the mass spectrum thereof according to FAB-MS has a peak of m/z of 559 [M+H].sup.+ ; (2) the molecule bears 26 carbon atoms and no nitrogen atom; (3) the ultraviolet absorption spectrum thereof in methianol shows a terminal absorptions; (4) the main absorption wavenumbers of the infrared absorption spectrum according to the KBr method are 3430, 2920, 2850, 1740, and 1190 cm.sup.-1 ; and (5) they are soluble in methanol, chloroform, and water, but are sparingly soluble in hexane.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: May 30, 2000
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Takesako Kazutoh, Yoshie Yoshikawa, Eiko Koyama, Tomoko Masuda, Ikunoshin Kato
  • Patent number: 5652226
    Abstract: The compound of the formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, are described. These compounds are antibacterial agents.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: July 29, 1997
    Assignee: Schering Corporation
    Inventors: Viyyoor M. Girijavallabhan, Anil K. Saksena, Frank Bennett, Edwin Jao, Naginbhai M. Patel, Ashit Ganguly
  • Patent number: 5567676
    Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 22, 1996
    Assignee: Gruppo Lepetit S.p.A
    Inventors: Enrico Selva, Grazia Beretta, Angelo Borghi, Maurizio Denaro
  • Patent number: 5514649
    Abstract: The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270 factor C.sub.2a, the addition salts thereof, the pharmaceutical compositions thereof and its use as medicament, particularly in the treatment of infectious diseases involving microorganisms susceptible to it and its use as animal growth promoter.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: May 7, 1996
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Enrico Selva, Sergio Stella, Luigi Colombo, Maurizio Denaro
  • Patent number: 5476656
    Abstract: Substance BS-3, a polysaccharide, produced by a microorganism belonging to the genus Klebsiella is disclosed, BS-3 having the following properties: main constituting sugar: rhamnose, galactose, glucose, and glucuronic acid; white to pale brown powder; easily soluble in water and sparingly soluble in methanol, ethyl acetate, benzene, etc.; viscosity: 1 to 8,000 cps; molecular weight: 1,000 to 10,000,000; positive in phenol-sulfuric acid reaction, carbazole-sulfuric acid reaction, Molisch's reaction, and ninhydrin reaction. BS-3 is useful as a heat-resistance stabilizer for a fat and oil emulsion and an anti-oxidant for fats and oils in an emulsion and also as an analgesic composition.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: December 19, 1995
    Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
    Inventors: Katsumi Kawaguchi, Eiichi Takahashi, Mitsuhiko Nishiki, Satoshi Fujimoto, Toshiya Kase
  • Patent number: 5456910
    Abstract: Novel antibiotic stalobacins A to I having physico-chemical properties as shown in Tables 1 to 4 are provided, which are excellent antibiotics showing marked effects on Gram-positive bacteria.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: October 10, 1995
    Assignee: Shionogi & Co., Ltd.
    Inventors: Shigeru Matsutani, Tadashi Yoshida, Ryuji Sakazaki, Koichi Matsumoto, Shigeo Yagi, Bunji Kageyama, Yoshimi Kawamura, Toshiyuki Kamigauchi, Susumu Kamata